A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer (TNBC) with a win in a phase 3 combination trial with MSD's PD-1 inhibitor Keytruda. ASCENT-04/KEYNOTE ...
EatingWell on MSN
The FDA Issues Recall After Finding Lead in Cookware—This Is What’s Safe to Use Instead
If you’re anything like me, you’re moving toward better choices—in life, but also in the kitchen. No more wasting money on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback